Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate

被引:1
作者
Kaneko, F
Saito, H
Saito, Y
Wakabayashi, K
Nakamoto, N
Tada, S
Suzuki, H
Tsunematsu, S
Kumagai, N
Ishii, H
机构
[1] Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan
[2] Kitasato Inst Hosp, Dept Internal Med, Ctr Liver, Minato Ku, Tokyo 1088642, Japan
关键词
invasion; matrix metalloproteinase; hepatocellular carcinoma; type; 1; interferon; sodium butyrate;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have demonstrated anti-proliferation and anti-metastasis effects of both interferon-a and a historic deacetylase inhibitor, sodium butyrate, on human liver cancer cell lines. In this study, invasive ability of human liver cancer cell lines through the matrix-coated membrane was examined and inhibitory effect of interferon-cc and sodium butyrate was investigated. Among six human liver cancer cell lines, HLE and HLF showed high invasive ability using the Matrigel invasion assay. This invasion ability was significantly inhibited by pretreatment of the cells with 1000 IU/ml of interferon-alpha or 2 mM of sodium butyrate. Gelatin zymography and the matrix metalloproteinase-2 and -9 activity assay showed that these two cell lines produce active- and pro-matrix metalloproteinase-2 and -9, and their activity was significantly reduced by pretreatment with both agents. Real-time quantitative reverse transcription-polymerase chain reaction showed decrease in matrix metalloproteinase-1 mRNA levels by pretreatment with both agents, but mRNA levels of tissue inhibitor of matrix metalloproteinase-1 and -2 were differently modulated by interferon-alpha and sodium butyrate. These results suggest that interteron-alpha and sodium butyrate reduce a chance of invasion and metastasis of human liver cancer cells by inhibiting matrix metalloproteinase activity, although its inhibitor is differently regulated.
引用
收藏
页码:837 / 845
页数:9
相关论文
共 65 条
[1]  
Arii S, 1996, HEPATOLOGY, V24, P316
[2]   Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan [J].
Arii, S ;
Yamaoka, Y ;
Futagawa, S ;
Inoue, K ;
Kobayashi, K ;
Kojiro, M ;
Makuuchi, M ;
Nakamura, Y ;
Okita, K ;
Yamada, R .
HEPATOLOGY, 2000, 32 (06) :1224-1229
[3]   The function of type I interferons in antimicrobial immunity [J].
Bogdan, C .
CURRENT OPINION IN IMMUNOLOGY, 2000, 12 (04) :419-424
[4]   Treatment of chronic hepatitis C: A systematic review [J].
Chander, G ;
Sulkowski, MS ;
Jenckes, MW ;
Torbenson, MS ;
Herlong, HF ;
Bass, EB ;
Gebo, KA .
HEPATOLOGY, 2002, 36 (05) :S135-S144
[5]   Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells [J].
Chung, TW ;
Moon, SK ;
Lee, YC ;
Kim, JG ;
Ko, JH ;
Kim, CH .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2002, 408 (02) :147-154
[6]   Radiofrequency ablation of malignant liver tumors [J].
Curley, SA .
ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (04) :338-347
[7]   Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells [J].
Detjen, KM ;
Welzel, M ;
Farwig, K ;
Brembeck, FH ;
Kaiser, A ;
Riecken, EO ;
Wiedenmann, B ;
Rosewicz, S .
GASTROENTEROLOGY, 2000, 118 (04) :735-748
[8]  
DOI I, 1975, GANN, V66, P385
[9]  
Ebinuma H, 1999, INT J ONCOL, V15, P991
[10]   Reduction of c-myc expression by an antisense approach under Cre/loxP switching induces apoptosis in human liver cancer cells [J].
Ebinuma, H ;
Saito, H ;
Kosuga, M ;
Wakabayashi, K ;
Saito, Y ;
Takagi, T ;
Nakamoto, N ;
Okuyama, T ;
Ishii, H .
JOURNAL OF CELLULAR PHYSIOLOGY, 2001, 188 (01) :56-66